Ranbaxy, GlaxoSmithKline settle matters over Sumatriptan Succinate

New Delhi, Jan 21 (UNI) Ranbaxy Laboratories Ltd today announced that it has settled all matters relating to possible patent litigation with GlaxoSmithKline over Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex Tablets.

The terms of the settlement, provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate Tablets (in the 25 mg,50 mg and 100 mg strengths) in the United States with an expected launch date in December, 2008.

Additional terms of the settlement agreement were not disclosed.

The annual market sales for Sumatriptan Succinate (Imitrex) is 985 million dollars.

Ranbaxy Laboratories Ltd, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of generic medicines.

UNI BJR PBB RN1445